At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 224 enrolled
Drug / intervention
AR-13324 Ophthalmic Solution 0.01% +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Double-masked, Randomized, Multi-center, Active-controlled, Dose-response Parallel-group Study Comparing the Safety and Ocular Hypotensive Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure
In Brief
A Phase 2 clinical trial evaluating AR-13324 Ophthalmic Solution 0.01%, AR-13324 Ophthalmic Solution 0.02%, and 1 other intervention for Ocular Hypertension and Open Angle Glaucoma. Completed, enrolled 224 participants across 22 sites.
Detailed Summary
Double-masked, randomized, multi-center, dose-response, active-controlled parallel-comparison of AR-13324 to latanoprost
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOcular Hypertension, Open Angle Glaucoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2012
First PostedNov 2012
Primary CompletionMay 2013
TodayJul 2026
First PostedNov 21, 2012
Enrollment StartNov 1, 2012
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.6 years ago
Interventions
AR-13324 Ophthalmic Solution 0.01%drug
Administered to study eye, once daily (QD) in the evening (PM) for 28 days
AR-13324 Ophthalmic Solution 0.02%drug
Administered to study eye, QD in the PM for 28 days
Latanoprost ophthalmic solution 0.005%drug
Administered to study eye, QD in the PM for 28 days